# XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer

> **NCT06568562** · PHASE2 · RECRUITING · sponsor: **University of Utah** · enrollment: 32 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** XL092

## Key facts

- **NCT ID:** NCT06568562
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-09
- **Primary completion:** 2026-12
- **Final completion:** 2028-12
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-12-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06568562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06568562, "XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06568562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*